Oral Treatment of Obesity by GLP
Several lines of evidence have revealed that GLP-1 and its analogs possess cardioprotective effects by various mechanisms related to cardiac contractility, myocardial glucose uptake, cardiac oxidative stress and ischemia/reperfusion injury, and mitochondrial homeostasis.
Key Details About Oleucine Glp-1 Analog Prevention Effects
Glucagon-like peptide-1 ( GLP-1 ) analogs such as liraglutide are well established for metabolic disorders 1,2,3; however, their neuropsychiatric effects remain enigmatic. Clinical studies have shown conflicting findings on the mental health risks of GLP-1 analogs . While obese patients treated with liraglutide and semaglutide present a higher risk of depression, anxiety, and suicidal behavior, 4 ...
Anti-diabetic effects of incretins are mediated by multiple organs, and their effect on adipose tissue has remained unclear. Gutierrez et al. discover that GLP1 analogs induce IL-6 secretion by monocytes and show that IL-6 signaling in adipocytes activates brown adipogenesis and thermogenesis that contributes to anti-diabetic effects of GLP1 analogs .
Pleiotropic Effects of GLP
In this review, we provide a comprehensive description of the diverse roles for GLP-1 across multiple tissues, describe downstream pathways stimulated by acute and chronic exposure, and discuss novel pleiotropic applications of GLP-1 mimetics in the treatment of human disease.
This review investigates the side effects of glucagon-like peptide-1 receptor agonists ( GLP -1RAs) like liraglutide, semaglutide, and tirzepatide, medications known for their efficacy in promoting weight loss among individuals with obesity. The rationale is rooted in understanding the balance between their therapeutic benefits and associated risks.
Changes in food preferences and ingestive behaviors after ...
Glucagon-like peptide-1 ( GLP-1 ) analogs are approved for the treatment of obesity in adults and adolescents. Reports have emerged that the weight loss effect of these medications may be related to ...
The administration of Lys, Leu, Ile, Phe, or Glu by oral gavage resulted in Leu and Lys increasing circulating the satiety hormone CCK, and Phe stimulating the release of the incretin GLP-1 . The effect of Phe on GLP-1 was sustained beyond 90 min and triggered a positive correlation with CCK indicating the likely existence of feedback mechanisms between proximal and distal regions of the small ...
Abstract Glucagon-like peptide-1 ( GLP-1 ) is abundant in the circulation, and it is well-known to regulate glucose homeostasis, feeding, and body weight. GLP-1 receptor agonists are therefore approved for treating type 2 diabetes and obesity. However, more recent research has demonstrated that GLP-1 acts within the brain to modulate reward responses, thereby highlighting GLP-1 as a potential ...
Clinical scenarios representing common situations in daily practice, and infographics useful to guide both HCPs and patients, are included. These recommendations may prevent people with T2D and/or obesity from withdrawing from GLP-1 RAs treatment, thus benefitting from their superior effect on glycaemic control and weight loss.
